FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.23
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$27.50

19 May
2026

0.830

OPEN

$26.82

3.11%

HIGH

$27.62

694,387

LOW

$26.71

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 69.0 xxx
DPS (cps) 40.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 39.7 xxx
Dividend Yield 1.5% xxx
Div Pay Ratio(%) 59.2% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.38%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.27

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/12 - (franking ex-div 22.35c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx58.6
DPS All xxxxxxxxxxxxxxx45.5
Sales/Revenue xxxxxxxxxxxxxxx1,842.0 M
Book Value Per Share xxxxxxxxxxxxxxx293.2
Net Operating Cash Flow xxxxxxxxxxxxxxx499.4 M
Net Profit Margin xxxxxxxxxxxxxxx18.64 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx20.62 %
Return on Invested Capital xxxxxxxxxxxxxxx19.75 %
Return on Assets xxxxxxxxxxxxxxx15.57 %
Return on Equity xxxxxxxxxxxxxxx20.62 %
Return on Total Capital xxxxxxxxxxxxxxx25.59 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx254.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx79 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx139 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx240 M
Price To Book Value xxxxxxxxxxxxxxx10.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx93.8 M
Capex % of Sales xxxxxxxxxxxxxxx5.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx683 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx693 M
Research & Development xxxxxxxxxxxxxxx207 M
Investments - Total xxxxxxxxxxxxxxx35 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

06/05/2026

1

Overweight

-

-

Morgan Stanley assesses oil-linked risks in the Australian Healthcare sector, identifying Ramsay Health Care and Sonic Healthcare as the most exposed to cost inflation driven by higher oil prices.

Oil now presents a cost headwind for the sector, increasing component, consumables and freight expenses.

Lower margins and limited pricing power amplify earnings sensitivity for Ramsay and Sonic, the analysts explain. ResMed and Fisher & Paykel Healthcare are viewed as best positioned, supported by higher margins and stronger pricing power.

Overweight rating maintained for Fisher & Paykel Healthcare. Target falls to NZ$40 from NZ$44.20. Industry View: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY26 dividend of 42.89 cents and EPS of 68.58 cents.
Morgan Stanley forecasts a full year FY27 dividend of 56.96 cents and EPS of 80.20 cents.

UBS

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

03/03/2026

1

Buy

$37.50

36.36%

Fisher & Paykel Healthcare has raised FY26 revenue guidance to NZ$2.3bn from NZ$2.17-2.27bn, around 1.5% above forecasts by Canaccord Genuity and consensus.

Profit guidance was also upgraded to NZ$450-470m from NZ$410-460m, 4% ahead of the broker's expectations at the top end, driven by strong hospital demand for high-flow nasal cannula products.

The analysts view the upgrades as operationally driven, with margin expansion offsetting tariff headwinds and limited FX impact.

The broker expects FY26 profit of NZ$466.8m and makes modest 1-3% upgrades to its outer-year forecasts. Target of $37.50 and Buy rating are retained.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 39.31 cents and EPS of 69.01 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 48.92 cents and EPS of 76.88 cents.
Access Extra Coverage Research History >

FPH STOCK CHART

FNArena News on FPH

1
Rudi’s View: AI Is Making A Come-Back

May 13 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – May 12, 2026

May 12 2026 - Daily Market Reports
3
Rudi’s View: AI, The Great Market Divider

May 06 2026 - Rudi's View
4
Rudi’s View: Stagflation, No Recession

Apr 30 2026 - Rudi's View
5
Rudi’s View: Post-February Conviction Calls

Mar 12 2026 - Rudi's View

Latest Medical Equipment & Devices News

1
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
2
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
3
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
4
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
5
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
6
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
7
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
8
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
9
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
10
ResMed’s New Level Of Support

Jul 29 2025 - Technicals